Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002

Clinical Therapeutics

Volumn 30, Issue 12, 2008, Pages 2335-2341

  Frei, Christopher R ^a,b   Burgess, David S ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

aerobic gram negative bacteria; infectious disease; Monte Carlo simulation; piperacillin tazobactam; pulmonary disease

Indexed keywords

PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; COMPUTER MODEL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTENSIVE CARE; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MONTE CARLO METHOD; NONHUMAN; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER BAUMANNII; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; INTENSIVE CARE UNITS; LUNG DISEASES; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PATIENT ADMISSION; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; UNITED STATES;

EID: 58249144763     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.12.009     Document Type: Article

References (24)

1. Tenover F.C. Mechanisms of antimicrobial resistance in bacteria. Am J Med. 119 Suppl 1 (2006) S3-S10 discussion S62-S70
2. Fass R.J., and Prior R.B. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother. 33 (1989) 1268-1274
3. Itokazu G.S., Quinn J.P., Bell-Dixon C., et al. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: Evaluation of a national postmarketing surveillance program. Clin Infect Dis. 23 (1996) 779-784
4. Neuhauser M.M., Weinstein R.A., Rydman R., et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 289 (2003) 885-888
5. Burgess D.S., and Frei C.R. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother. 56 (2005) 893-898
6. Kuti J.L., Nightingale C.H., and Nicolau D.P. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002. Antimicrob Agents Chemother. 48 (2004) 2464-2470
7. Masterton R.G., Kuti J.L., Turner P.J., and Nicolau D.P. The OPTAMA programme: Utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe [published correction appears in J Antimicrob Chemother. 2005;56:990]. J Antimicrob Chemother 55 (2005) 71-77
8. Craig W.A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 22 (1995) 89-96
9. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis. 26 (1998) 1-10
10. Drusano G.L. Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'. Nat Rev Microbiol. 2 (2004) 289-300
11. White R.L. What in vitro models of infection can and cannot do. Pharmacotherapy 21 (2001) 292S-301S
12. CLSI/NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (2003), NCCLS, Wayne, Pa Approved standard M7-A6
13. Occhipinti D.J., Pendland S.L., Schoonover L.L., et al. Pharmacokinetics and pharmacodynamics of two multipledose piperacillin-tazobactam regimens. Antimicrob Agents Chemother. 41 (1997) 2511-2517
14. Zosyn® (piperacillin and tazobactam for injection) [prescribing information] (November 2007), Wyeth Pharmaceuticals, Inc, Philadelphia, Pa. http://www.wyeth.com/content/showlabeling.asp?id=477 Accessed October 7, 2008
15. Turnidge J.D. The pharmacodynamics of beta-lactams. Clin Infect Dis. 27 (1998) 10-22
16. DeRyke C.A., Kuti J.L., and Nicolau D.P. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis. 58 (2007) 337-344
17. Burgess D.S., Frei C.R., Lewis Ii J.S., et al. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis. Clin Microbiol Infect. 13 (2007) 33-39
18. Frei C.R., Hampton S.L., and Burgess D.S. Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: A data analysis. Clin Ther. 28 (2006) 1035-1040
19. Ambrose P.G., and Grasela D.M. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: Fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 38 (2000) 151-157
20. Frei C.R., and Burgess D.S. Pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation. Pharmacotherapy. 25 (2005) 1161-1167
21. Kuti J.L., Florea N.R., Nightingale C.H., and Nicolau D.P. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Pharmacotherapy. 24 (2004) 8-15
22. Burgess D.S., and Waldrep T. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. Clin Ther. 24 (2002) 1090-1104
23. Frei C.R., and Burgess D.S. Continuous infusion beta-lactams for intensive care unit pulmonary infections. Clin Microbiol Infect. 11 (2005) 418-421
24. Lodise T.P., Lomaestro B., and Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 44 (2007) 357-363